Skip to content
Screener

CRISPR Therapeutics CRSP Net Change in Cash

Net Change in Cash at other companies

Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
-$49M-198%
Intellia Therapeutics logo
Intellia TherapeuticsNTLA
-$28.57M
Allogene Therapeutics logo
Allogene TherapeuticsALLO
-$21.38M+34.7%
Beam Therapeutics logo
Beam TherapeuticsBEAM
-$6.64M-103%
Sana Biotechnology logo
Sana BiotechnologySANA
$11.93M+138%
Design Therapeutics, Inc. logo
Design Therapeutics, Inc.DSGN
-$4.09M+54.1%

Other financials

Income statement

See full
Revenue$1.5M+68.6%
Operating income-$130.2M+12.2%
Net income-$122.9M+9.6%
EPS (diluted)-$1.28+19.0%

Balance sheet

See full
Cash & equivalents$423.3M+80.0%
Total debt$787.6M+259%
Total equity$1.8B-0.8%
Total assets$2.7B+25.8%

Cash flow

See full
Operating cash flow-$108.9M-102%
CapEx$504.0K+145%
Free cash flow-$109.4M-102%

Valuation

See full
Market cap$4.99B-2.6%
Enterprise value$5.36B+4.1%
P/S1,217×+1,082×

Profitability

See full
Operating margin-15,754.2%-17,253pp
Net margin-13,856.5%-15,058pp
FCF margin-9,777.6%-10,759pp

Returns & leverage

See full
Return on equity-31.2%+43.7pp
Debt / equity0.4×+0.3×
Current ratio18×+2.3×

Where this comes from

Reported directly by CRISPR Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.

The source filing: CRISPR Therapeutics’s 10-Q, filed May 4, 2026.

Filed
May 4, 2026, 4:48 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-204188
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Proceeds from exercise of options and ESPP contributions, net of issuance costs6,1582,072
Net cash provided by financing activities591,90810,588
Effect of exchange rate changes on cash(32)41
Increase (decrease) in cash72,236(63,073)
Cash, cash equivalents and restricted cash, beginning of period359,078309,776
Cash, cash equivalents and restricted cash, end of period$431,314$246,703
Supplemental disclosure of non-cash investing and financing activities
Equity issuance costs in accounts payable, accrued expenses, and other long-term liabilities$4,140$3,219

Item 1. Financial Statements

FAQ

What is CRISPR Therapeutics's net change in cash?
CRISPR Therapeutics (CRSP) reported net change in cash of $72.24M in Q1 2026.
How has CRISPR Therapeutics's net change in cash changed year-over-year?
CRISPR Therapeutics's net change in cash increased by 214.5% year-over-year, from -$63.07M to $72.24M.
What is the long-term trend for CRISPR Therapeutics's net change in cash?
Over 2 years (2021 to 2025), CRISPR Therapeutics's net change in cash has grown at a -55.2% compound annual growth rate (CAGR), from -$245.52M to $49.3M.
What does net change in cash mean?
Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.

Ask your AI about CRISPR Therapeutics's net change in cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude